The global hyaluronic viscosupplementation market was valued at US$ 2.3 Billion in 2022 and is expected to reach US$ 4.0 Billion by 2033. The three injection knee hyaluronic acid injections with around 49.1% in terms of value share, has topped the global Market within the product category in 2022 and is expected to grow at a CAGR of close to 5.2% over the forecast period (2023 to 2033)
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 2.3 Billion |
| Market Value 2023 | US$ 2.4 Billion |
| Market Value 2033 | US$ 4.0 Billion |
| CAGR 2023 to 2033 | 5.2% |
| Market Share of Top 5 Countries | 73.2% |
| Key Market Players | Anika Therapeutics Inc., Zimmer Biomet, Sanofi S.A., LG Chem, Chugai Pharmaceutical Co., Ltd., Meiji Seika Pharma co. ltd, Ferring B.V., Hanmi Pharm.Co.,Ltd., Anika Therapeutics, Inc., Fidia Farmaceutici s.p.a., Bioventus LLC, OrthogenRx, Seikagaku Corporation, Bioiberica S.A.U., APTISSEN, Hangzhou Singclean Medical Products Co.,Ltd, Maxigen Biotech Inc., TRB Chemedica International SA, Yuria-Pharm LLC, Haohai Biological Technology, and Chroma Pharma |
The injection of exogenous hyaluronic acid into diarthrodial joints restores synovial fluid characteristics, generating mechanical, analgesic, anti-inflammatory, and chondroprotective benefits. Hyaluronic acid is a polymer with a high viscosity and spatial structure. Rapid rehabilitation using hyaluronic acid filler offers relief from knee osteoarthritis, benefiting rheumatologists, rehabilitation providers, and primary care providers.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for hyaluronic viscosupplementation was around 24.4% of the overall US$ 9.56 Billion of the global hyaluronic acid based products market in 2022.
Knee osteoarthritis is a chronic degenerative condition that affects the structure of the joints and causes inflammation, leading to joint discomfort and functional restrictions. Significant population globally suffers from osteoarthritis, a multifactorial origin joint disease, with high prevalence in adults.
Because of its low allergic reaction rate, simplicity of injection, speedy recovery, repeatability, and quick effects, hyaluronic acid filler has gained popularity. Hyaluronic acid injections into the joints are another common procedure, particularly for individuals with osteoarthritis of the knees. In light of doctors' general reluctance to provide repeated injection of intra-articular corticosteroid injections, hyaluronic acid injection as a non-surgical therapeutic option have gained large popularity.
Owed to the above factors, the global market is projected to grow at CAGR of 5.2% in forecasted period.
Viscosupplementation offers a structural benefit in knee osteoarthritis treatment, with improved visual appearance and increased cartilage volume. One year after treatment, joint surface reconstitutes, with reduced loss of joint space. This results in a cost-effectiveness relationship and potential delay in total knee arthroplasty. First-line therapy for OA focuses on joint preservation and alleviating symptoms. Intra-articular hyaluronic acid injections (IAHA) are a promising nonsurgical treatment, particularly for mild-to-moderate OA and severe OA with comorbidities.
IAHA, a nonsurgical treatment modality, has gained popularity in managing knee OA, despite the lack of established disease-modifying treatments. Surgical methods for total knee replacement (TKR) are successful, although they have a risk-benefit ratio. Although intra-articular hyaluronic acid (IAHA) therapy or viscosupplementation have grown in recognition, there isn't enough solid research to back up their efficacy and safety.
IAHA gives patients with knee OA a little clinical benefit without safety issues, whereas viscosupplementation has a substantial benefit-to-risk ratio and speeds up TKR. IAHA improves knee OA by allowing lubrication, shock absorption, and re-establishing joint homeostasis through induction of endogenous HA production. It reduces analgesic usage to half and leads to a 40-month improvement in pain and joint function.
Price and synthesis of HA products vary, with some made synthetically through biotechnology, while others are derived from animals. These differences impact the healthcare system's economic impact. Stabilized hyaluronic acid, a new generation of HA preparations, offers a long half-life and high density, reducing injections and puncture risk in osteoarthritis treatment. Viscosupplementation saves money in the long run by postponing surgery for severe pain, allowing therapeutic prosthesis installation, and enhancing the patient's quality of life.
Principal Consultant
National and international guidelines discourage intra-articular hyaluronic acid derivatives. In countries like England, viscosupplementation is given low NHS funding priority due to the Institute's recommendation. HA injections in the knees are frequently associated with poor tolerance and failure rates, with anteromedial injections exhibiting up to 30% local reaction rates.
The efficacy of viscosupplementation is being questioned, which might be attributed to improper usage or a poorly fitted patient OA profile. A qualified expert is required for HA injection, which is difficult in a non-swollen joint. Some of research published claim hyaluronic viscosupplementation to be ineffective in osteoarthritis, these factors act as restraints for demand of hyaluronic viscosupplements.
The USA occupies 50.0% of market share in 2022 globally. As per British Medical Journal (BMJ-Clinical research ed.) 2022, Medicare, and commercial insurance companies increased viscosupplementation coverage, with hyaluronic acid injections becoming first-line treatment for knee osteoarthritis.
This makes USA prominent market for hyaluronic viscosupplementation in North America.
Japan expenditure on hyaluronic viscosupplementation in 2022 was US$ 198.4 Million.
OA education, weight management, self-management, and exercise are crucial for improving knee OA. However, few patients are willing to undergo surgery, especially in Japan. Surgeons may delay surgery for elderly or unwilling patients, and there is a disconnect between physicians and patients. Improved communication between physicians and patients is needed to better understand the potential benefits of surgery. This makes Japan a Lucrative market for hyaluronic viscosupplementation market.
In 2022, the China held a significant share in the East Asia market and contributed around US$ 157.8 Million. China faces a significant burden of knee osteoarthritis, affecting 250 million people worldwide and causing disability.
With a large population, more patients may require rehabilitation treatment and replacement, posing a significant public health burden for China. This makes China a large market for hyaluronic viscosupplements.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By product, three injection knee hyaluronic acid injections held 49.1% market share in world in 2022.
These injections were generally safe and showed a significant improvement in pain only at 6 months. However, more than or 5 injections were associated with a higher risk of treatment-related adverse events. Thus, demand for three injection knee hyaluronic acid injections are predicted to expand rapidly between 2023 and 2033.
Why Molecular Weight is Preferred Prominently in Hyaluronic Viscosupplementation?
The market value of high molecular weight hyaluronic viscosupplementation is US$ 1.6 Billion, representing a sizable 68.8% market share in 2022. Hyaluronic acid is a high molecular weight polysaccharide used in various applications. The topic of molecular weight and hyaluronic acid's protective physicochemical functions remains controversial.
Most studies show a direct correlation between molecular weight and its effects on synoviocytes. However, some authors believe in vivo effects may differ due to excessive molecular size, preventing its ability to move from intra-articular to intercellular environments. The relationship between molecular weight and analgesia is evident in both in vitro and in vivo results, with products with molecular weight between 0.5 and 1 x 106 Da showing the best in vivo effects. Hence, high molecular weight hyaluronic viscosupplementation is preferred prominently.
By body part, the knee accounted for the prominent share in the global hyaluronic viscosupplementation market, with a revenue share of 85.2% in 2022. This segment is expected to continue holding prominent market share by the end of forecast period.
Viscosupplementation is an outpatient procedure for knees, with application method well established. Quantity and frequency depend on product characteristics and professional experience. Viscosupplementation in knee osteoarthritis has been observed to increase cartilage volume, with biopsies showing better matrix quality and increased chondrocyte density. This treatment may present a cost-effectiveness relationship, potentially reducing joint space loss.
The ambulatory surgical centers have a considerable presence in the hyaluronic viscosupplementation market, accounting for 31.7% value share in 2022, and exhibiting a high CAGR of 5.5% over the forecast period. Pseudosepsis cases submitted to the FDA, including those involving injections of non-cross-linked hyaluronic acid, necessitate rehabilitative therapy and anti-inflammatory medications. Ambulatory surgical centers offer expert guidance and 24/7 care, benefiting end users in the hyaluronic viscosupplementation market.
Collaborations and collaborations among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten hyaluronic viscosupplementation. Collaboration in research, development, and commercialization can lead to market expansion and the creation of new applications. Numerous large firms compete in the field of hyaluronic viscosupplementation. Among the well-known players in this field are:
Similarly, recent developments related to the company’s manufacturing the hyaluronic viscosupplementation injections have been tracked by the team at Future Market Insights, which are available in the full report.
| Attributes | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | US$ Million for Value, Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, United Kingdom, Spain, BENELUX, Russia, Nordics, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Israel, Northern Africa and South Africa. |
| Key Market Segments Covered | Product, Body Part, Molecular Weight, Indication, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market registers US$ 2.4 billion in revenue in 2023.
The global market revenue is projected to exceed US$ 4.0 billion by 2033.
Sales of hyaluronic viscosupplementation is expected to record a 5.2% CAGR through 2033.
Hyaluronic viscosupplementation boasts substantial revenue prospects in Japan.
The market secured US$ 2.3 billion revenue in 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Application of HA and its derivatives
4.2. Available Treatment for Knee Osteoarthritis
4.3. Disease Epidemiology by Key Country
4.4. Current and proposed pathways leading to the Frozen Shoulder Syndrome
4.5. Product Adoption Analysis, By Region
4.6. Pipeline Assessment
4.7. Regulatory Scenario, By Country
4.8. White Space Opportunities
4.9. Product v/s Generation Matrix
4.10. Reimbursement Landscape by Country
4.11. Porter’s Analysis
4.12. PESTLE Analysis
4.13. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Life Expectancy Outlook
5.1.3. Global Geriatric Population Overview
5.1.4. Global Hyaluronic Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Historical Growth of Top Companies
5.2.2. Ease of Treatment in Outpatient Basis
5.2.3. Healthcare Bodies Advocating Adoption of Combat Methodological Approach
5.2.4. Increased Treatment Efficiency
5.2.5. Rising Prevalence of Knee Osteoarthritis
5.2.6. Treatment Costs
5.2.7. Increasing Minimally Invasive Treatment Options
5.2.8. Improved Access to Healthcare Services
5.2.9. Integration of Digital Health Technologies
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand Volume (Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Volume (Units) Analysis, 2012 to 2022
6.2. Current and Future Market Volume (Units) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Market – Pricing Analysis
7.1. Regional Pricing Analysis By Product
7.2. Global Average Pricing Analysis Benchmark
7.3. Pricing Assumptions
8. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033
8.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022
8.2. Current and Future Market Size (US$ Million) Analysis and Forecast Projections, 2023 to 2033
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
8.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic
9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Product, 2012 to 2022
9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2023 to 2033
9.3.1. Single Injection Knee Hyaluronic Acid Injections
9.3.2. Three Injection Knee Hyaluronic Acid Injections
9.3.3. Five Injection Knee Hyaluronic Acid Injections
9.3.4. Next Generation (Steroid Combination)
9.4. Market Attractiveness Analysis By Product
10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Body Part
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Body Parts, 2012 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Body Parts, 2023 to 2033
10.3.1. Knee
10.3.2. Hip
10.3.3. Shoulder
10.3.4. Small Joints
10.3.5. Others
10.4. Market Attractiveness Analysis By Body Parts
11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Molecular Weight
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Molecular Weight, 2012 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Molecular Weight, 2023 to 2033
11.3.1. High Molecular Weight
11.3.2. Medium Molecular Weight
11.3.3. Low Molecular Weight
11.4. Market Attractiveness Analysis By Molecular Weight
12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Indication
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By Indication, 2012 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
12.3.1. Knee Osteoarthritis
12.3.2. Tendinopathies
12.3.3. Shoulder Arthritis
12.3.4. Hip Osteoarthritis
12.3.5. Frozen Shoulder
12.3.6. Ligament Injury
12.3.7. Post-Arthroscopy
12.3.8. Others
12.4. Market Attractiveness Analysis By Indication
13. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033
13.3.1. Hospitals
13.3.2. Ambulatory Surgical Centers
13.3.3. Orthopedic Clinics
13.3.4. Retail Pharmacies
13.3.5. Online Sales
13.4. Market Attractiveness Analysis By End User
14. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2012 to 2022
14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis Forecast By Region, 2023 to 2033
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. South Asia
14.3.5. East Asia
14.3.6. Oceania
14.3.7. Middle East and Africa
14.4. Market Attractiveness Analysis By Region
15. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. USA.
15.3.1.2. Canada
15.3.2. By Product
15.3.3. By Body Parts
15.3.4. By Molecular Weight
15.3.5. By Indication
15.3.6. By End User
15.4. Market Attractiveness Analysis By Region
15.4.1. By Country
15.4.2. By Product
15.4.3. By Body Parts
15.4.4. By Molecular Weight
15.4.5. By Indication
15.4.6. By End User
15.5. Market trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. USA. Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Body Parts
15.8.1.2.3. By Molecular Weight
15.8.1.2.4. By Indication
15.8.1.2.5. By End User
15.8.2. Canada Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product
15.8.2.2.2. By Body Parts
15.8.2.2.3. By Molecular Weight
15.8.2.2.4. By Indication
15.8.2.2.5. By End User
16. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
16.1. Introduction / Key Findings
16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Brazil
16.3.1.2. Mexico
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Product
16.3.3. By Body Parts
16.3.4. By Molecular Weight
16.3.5. By Indication
16.3.6. By End User
16.4. Market Attractiveness Analysis By Region
16.4.1. By Country
16.4.2. By Product
16.4.3. By Body Parts
16.4.4. By Molecular Weight
16.4.5. By Indication
16.4.6. By End User
16.5. Market trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Brazil Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Body Parts
16.8.1.2.3. By Molecular Weight
16.8.1.2.4. By Indication
16.8.1.2.5. By End User
16.8.2. Mexico Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Body Parts
16.8.2.2.3. By Molecular Weight
16.8.2.2.4. By Indication
16.8.2.2.5. By End User
16.8.3. Argentina Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product
16.8.3.2.2. By Body Parts
16.8.3.2.3. By Molecular Weight
16.8.3.2.4. By Sample
16.8.3.2.5. By End User
17. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033
17.1. Introduction / Key Findings
17.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. France
17.3.1.3. Spain
17.3.1.4. Russia
17.3.1.5. Italy
17.3.1.6. BENELUX
17.3.1.7. United Kingdom.
17.3.1.8. Nordics
17.3.1.9. Rest of Europe
17.3.2. By Product
17.3.3. By Body Parts
17.3.4. By Molecular Weight
17.3.5. By Indication
17.3.6. By End User
17.4. Market Attractiveness Analysis By Region
17.4.1. By Country
17.4.2. By Product
17.4.3. By Body Parts
17.4.4. By End User
17.5. Market trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Germany Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product
17.8.1.2.2. By Body Parts
17.8.1.2.3. By Molecular Weight
17.8.1.2.4. By Indication
17.8.1.2.5. By End User
17.8.2. France Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product
17.8.2.2.2. By Body Parts
17.8.2.2.3. By Molecular Weight
17.8.2.2.4. By Indication
17.8.2.2.5. By End User
17.8.3. Spain Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Product
17.8.3.2.2. By Body Parts
17.8.3.2.3. By Molecular Weight
17.8.3.2.4. By Sample
17.8.3.2.5. Type By End User
17.8.4. Russia Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Product
17.8.4.2.2. By Body Parts
17.8.4.2.3. By Molecular Weight
17.8.4.2.4. By Sample
17.8.4.2.5. Type By End User
17.8.5. Italy Market Analysis
17.8.5.1. Introduction
17.8.5.2. Market Analysis and Forecast by Market Taxonomy
17.8.5.2.1. By Product
17.8.5.2.2. By Body Parts
17.8.5.2.3. By Molecular Weight
17.8.5.2.4. By Indication
17.8.5.2.5. By End User
17.8.6. BENELUX Market Analysis
17.8.6.1. Introduction
17.8.6.2. Market Analysis and Forecast by Market Taxonomy
17.8.6.2.1. By Product
17.8.6.2.2. By Body Parts
17.8.6.2.3. By Molecular Weight
17.8.6.2.4. By Indication
17.8.6.2.5. By End User
17.8.7. United Kingdom. Market Analysis
17.8.7.1. Introduction
17.8.7.2. Market Analysis and Forecast by Market Taxonomy
17.8.7.2.1. By Product
17.8.7.2.2. By Body Parts
17.8.7.2.3. By Molecular Weight
17.8.7.2.4. By Indication
17.8.7.2.5. By End User
17.8.8. Nordics Market Analysis
17.8.8.1. Introduction
17.8.8.2. Market Analysis and Forecast by Market Taxonomy
17.8.8.2.1. By Product
17.8.8.2.2. By Body Parts
17.8.8.2.3. By Molecular Weight
17.8.8.2.4. By Indication
17.8.8.2.5. By End User
18. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
18.1. Introduction / Key Findings
18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Product
18.3.3. By Body Parts
18.3.4. By Molecular Weight
18.3.5. By Indication
18.3.6. By End User
18.4. Market Attractiveness Analysis By Region
18.4.1. By Country
18.4.2. By Product
18.4.3. By Body Parts
18.4.4. By Molecular Weight
18.4.5. By Indication
18.4.6. By End User
18.5. Market trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. China Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Product
18.8.1.2.2. By Body Parts
18.8.1.2.3. By Molecular Weight
18.8.1.2.4. By Indication
18.8.1.2.5. By End User
18.8.2. Japan Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Product
18.8.2.2.2. By Body Parts
18.8.2.2.3. By Molecular Weight
18.8.2.2.4. By Indication
18.8.2.2.5. By End User
18.8.3. South Korea Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Product
18.8.3.2.2. By Body Parts
18.8.3.2.3. By Molecular Weight
18.8.3.2.4. By Indication
18.8.3.2.5. By End User
19. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
19.1. Introduction / Key Findings
19.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. India
19.3.1.2. Indonesia
19.3.1.3. Thailand
19.3.1.4. Philippines
19.3.1.5. Malaysia
19.3.1.6. Vietnam
19.3.1.7. Rest of South Asia
19.3.2. By Product
19.3.3. By Body Parts
19.3.4. By Molecular Weight
19.3.5. By Indication
19.3.6. By End User
19.4. Market Attractiveness Analysis By Region
19.4.1. By Country
19.4.2. By Product
19.4.3. By Body Parts
19.4.4. By Molecular Weight
19.4.5. By Indication
19.4.6. By End User
19.5. Market trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. India Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Product
19.8.1.2.2. By Body Parts
19.8.1.2.3. By Molecular Weight
19.8.1.2.4. By Indication
19.8.1.2.5. By End User
19.8.2. Indonesia Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Product
19.8.2.2.2. By Body Parts
19.8.2.2.3. By Molecular Weight
19.8.2.2.4. By Indication
19.8.2.2.5. By End User
19.8.3. Thailand Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Product
19.8.3.2.2. By Body Parts
19.8.3.2.3. By Molecular Weight
19.8.3.2.4. By Indication
19.8.3.2.5. By End User
19.8.4. Philippines Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Product
19.8.4.2.2. By Body Parts
19.8.4.2.3. By Molecular Weight
19.8.4.2.4. By Indication
19.8.4.2.5. By End User
19.8.5. Malaysia Market Analysis
19.8.5.1. Introduction
19.8.5.2. Market Analysis and Forecast by Market Taxonomy
19.8.5.2.1. By Product
19.8.5.2.2. By Body Parts
19.8.5.2.3. By Molecular Weight
19.8.5.2.4. By Indication
19.8.5.2.5. By End User
19.8.6. Vietnam Market Analysis
19.8.6.1. Introduction
19.8.6.2. Market Analysis and Forecast by Market Taxonomy
19.8.6.2.1. By Product
19.8.6.2.2. By Body Parts
19.8.6.2.3. By Molecular Weight
19.8.6.2.4. By Indication
19.8.6.2.5. By End User
20. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033
20.1. Introduction / Key Findings
20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
20.3. Current and Future Market Size (US$ Million) Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Product
20.3.3. By Body Parts
20.3.4. By Molecular Weight
20.3.5. By Indication
20.3.6. By End User
20.4. Market Attractiveness Analysis By Region
20.4.1. By Country
20.4.2. By Product
20.4.3. By Body Parts
20.4.4. By End User
20.5. Market trends
20.6. Key Market Participants - Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
20.8. Country Level Analysis & Forecast
20.8.1. Australia Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast by Market Taxonomy
20.8.1.2.1. By Product
20.8.1.2.2. By Body Parts
20.8.1.2.3. By Molecular Weight
20.8.1.2.4. By Indication
20.8.1.2.5. By End User
20.8.2. New Zealand Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast by Market Taxonomy
20.8.2.2.1. By Product
20.8.2.2.2. By Body Parts
20.8.2.2.3. By Molecular Weight
20.8.2.2.4. By Indication
20.8.2.2.5. By End User
21. Middle East and Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033
21.1. Introduction / Key Findings
21.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
21.3. Current and Future Market Size (US$ Million) Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Türkiye
21.3.1.3. Israel
21.3.1.4. South Africa
21.3.1.5. Northern Africa
21.3.1.6. Rest of Middle East and Africa
21.3.2. By Product
21.3.3. By Body Parts
21.3.4. By Molecular Weight
21.3.5. By Indication
21.3.6. By End User
21.4. Market Attractiveness Analysis By Region
21.4.1. By Country
21.4.2. By Product
21.4.3. By Body Parts
21.4.4. By Molecular Weight
21.4.5. By Indication
21.4.6. By End User
21.5. Market trends
21.6. Key Market Participants - Intensity Mapping
21.7. Drivers and Restraints - Impact Analysis
21.8. Country Level Analysis & Forecast
21.8.1. GCC Countries Market Analysis
21.8.1.1. Introduction
21.8.1.2. Market Analysis and Forecast by Market Taxonomy
21.8.1.2.1. By Product
21.8.1.2.2. By Body Parts
21.8.1.2.3. By Molecular Weight
21.8.1.2.4. By Indication
21.8.1.2.5. By End User
21.8.2. Türkiye Market Analysis
21.8.2.1. Introduction
21.8.2.2. Market Analysis and Forecast by Market Taxonomy
21.8.2.2.1. By Product
21.8.2.2.2. By Body Parts
21.8.2.2.3. By Molecular Weight
21.8.2.2.4. By Indication
21.8.2.2.5. By End User
21.8.3. Israel Market Analysis
21.8.3.1. Introduction
21.8.3.2. Market Analysis and Forecast by Market Taxonomy
21.8.3.2.1. By Product
21.8.3.2.2. By Body Parts
21.8.3.2.3. By Molecular Weight
21.8.3.2.4. By Indication
21.8.3.2.5. By End User
21.8.4. South Africa Market Analysis
21.8.4.1. Introduction
21.8.4.2. Market Analysis and Forecast by Market Taxonomy
21.8.4.2.1. By Product
21.8.4.2.2. By Body Parts
21.8.4.2.3. By Molecular Weight
21.8.4.2.4. By Indication
21.8.4.2.5. By End User
21.8.5. Northern Africa Market Analysis
21.8.5.1. Introduction
21.8.5.2. Market Analysis and Forecast by Market Taxonomy
21.8.5.2.1. By Product
21.8.5.2.2. By Body Parts
21.8.5.2.3. By Molecular Weight
21.8.5.2.4. By Indication
21.8.5.2.5. By End User
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players (%)
22.3. Market Concentration
22.4. Market Presence Analysis
22.4.1. Regional Footprint of Players
22.4.2. Product Footprint of Players
22.4.3. Channel Footprint of Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Key Development Analysis
23.3. Branding and Promotional Strategies, By Key Players
23.4. Competition Deep Dive
23.4.1. Anika Therapeutics
23.4.1.1. Overview
23.4.1.2. Product Portfolio
23.4.1.3. Key Financials
23.4.1.4. Sales Footprint
23.4.1.5. SWOT Analysis
23.4.1.6. Strategy Overview
23.4.1.6.1. Marketing Strategies
23.4.1.6.2. Channel Strategies
23.4.1.6.3. Product Strategies
23.4.2. Zimmer Biomet
23.4.2.1. Overview
23.4.2.2. Product Portfolio
23.4.2.3. Key Financials
23.4.2.4. Sales Footprint
23.4.2.5. SWOT Analysis
23.4.2.6. Strategy Overview
23.4.2.6.1. Marketing Strategies
23.4.2.6.2. Channel Strategies
23.4.2.6.3. Product Strategies
23.4.3. Sanofi S.A.
23.4.3.1. Overview
23.4.3.2. Product Portfolio
23.4.3.3. Key Financials
23.4.3.4. Sales Footprint
23.4.3.5. SWOT Analysis
23.4.3.6. Strategy Overview
23.4.3.6.1. Marketing Strategies
23.4.3.6.2. Channel Strategies
23.4.3.6.3. Product Strategies
23.4.4. LG Chem
23.4.4.1. Overview
23.4.4.2. Product Portfolio
23.4.4.3. Key Financials
23.4.4.4. Sales Footprint
23.4.4.5. SWOT Analysis
23.4.4.6. Strategy Overview
23.4.4.6.1. Marketing Strategies
23.4.4.6.2. Channel Strategies
23.4.4.6.3. Product Strategies
23.4.5. Chugai Pharmaceutical Co., Ltd.
23.4.5.1. Overview
23.4.5.2. Product Portfolio
23.4.5.3. Key Financials
23.4.5.4. Sales Footprint
23.4.5.5. SWOT Analysis
23.4.5.6. Strategy Overview
23.4.5.6.1. Marketing Strategies
23.4.5.6.2. Channel Strategies
23.4.5.6.3. Product Strategies
23.4.6. Meiji Seika Pharma co. ltd
23.4.6.1. Overview
23.4.6.2. Product Portfolio
23.4.6.3. Key Financials
23.4.6.4. Sales Footprint
23.4.6.5. SWOT Analysis
23.4.6.6. Strategy Overview
23.4.6.6.1. Marketing Strategies
23.4.6.6.2. Channel Strategies
23.4.6.6.3. Product Strategies
23.4.7. Ferring B.V.
23.4.7.1. Overview
23.4.7.2. Product Portfolio
23.4.7.3. Key Financials
23.4.7.4. Sales Footprint
23.4.7.5. SWOT Analysis
23.4.7.6. Strategy Overview
23.4.7.6.1. Marketing Strategies
23.4.7.6.2. Channel Strategies
23.4.7.6.3. Product Strategies
23.4.8. Hanmi Pharm.Co.,Ltd.
23.4.8.1. Overview
23.4.8.2. Product Portfolio
23.4.8.3. Key Financials
23.4.8.4. Sales Footprint
23.4.8.5. SWOT Analysis
23.4.8.6. Strategy Overview
23.4.8.6.1. Marketing Strategies
23.4.8.6.2. Channel Strategies
23.4.8.6.3. Product Strategies
23.4.9. Fidia Farmaceutici s.p.a.
23.4.9.1. Overview
23.4.9.2. Product Portfolio
23.4.9.3. Key Financials
23.4.9.4. Sales Footprint
23.4.9.5. SWOT Analysis
23.4.9.6. Strategy Overview
23.4.9.6.1. Marketing Strategies
23.4.9.6.2. Channel Strategies
23.4.9.6.3. Product Strategies
23.4.10. Bioventus LLC
23.4.10.1. Overview
23.4.10.2. Product Portfolio
23.4.10.3. Key Financials
23.4.10.4. Sales Footprint
23.4.10.5. SWOT Analysis
23.4.10.6. Strategy Overview
23.4.10.6.1. Marketing Strategies
23.4.10.6.2. Channel Strategies
23.4.10.6.3. Product Strategies
23.4.11. OrthogenRx
23.4.11.1. Overview
23.4.11.2. Product Portfolio
23.4.11.3. Key Financials
23.4.11.4. Sales Footprint
23.4.11.5. SWOT Analysis
23.4.11.6. Strategy Overview
23.4.11.6.1. Marketing Strategies
23.4.11.6.2. Channel Strategies
23.4.11.6.3. Product Strategies
23.4.12. Seikagaku Corporation
23.4.12.1. Overview
23.4.12.2. Product Portfolio
23.4.12.3. Key Financials
23.4.12.4. Sales Footprint
23.4.12.5. SWOT Analysis
23.4.12.6. Strategy Overview
23.4.12.6.1. Marketing Strategies
23.4.12.6.2. Channel Strategies
23.4.12.6.3. Product Strategies
23.4.13. Bioiberica S.A.U.
23.4.13.1. Overview
23.4.13.2. Product Portfolio
23.4.13.3. Key Financials
23.4.13.4. Sales Footprint
23.4.13.5. SWOT Analysis
23.4.13.6. Strategy Overview
23.4.13.6.1. Marketing Strategies
23.4.13.6.2. Channel Strategies
23.4.13.6.3. Product Strategies
23.4.14. APTISSEN
23.4.14.1. Overview
23.4.14.2. Product Portfolio
23.4.14.3. Key Financials
23.4.14.4. Sales Footprint
23.4.14.5. SWOT Analysis
23.4.14.6. Strategy Overview
23.4.14.6.1. Marketing Strategies
23.4.14.6.2. Channel Strategies
23.4.14.6.3. Product Strategies
23.4.15. Hangzhou Singclean Medical Products Co.,Ltd
23.4.15.1. Overview
23.4.15.2. Product Portfolio
23.4.15.3. Key Financials
23.4.15.4. Sales Footprint
23.4.15.5. SWOT Analysis
23.4.15.6. Strategy Overview
23.4.15.6.1. Marketing Strategies
23.4.15.6.2. Channel Strategies
23.4.15.6.3. Product Strategies
23.4.16. Maxigen Biotech Inc.
23.4.16.1. Overview
23.4.16.2. Product Portfolio
23.4.16.3. Key Financials
23.4.16.4. Sales Footprint
23.4.16.5. SWOT Analysis
23.4.16.6. Strategy Overview
23.4.16.6.1. Marketing Strategies
23.4.16.6.2. Channel Strategies
23.4.16.6.3. Product Strategies
23.4.17. TRB Chemedica International SA
23.4.18. Yuria-Pharm LLC
23.4.18.1. Overview
23.4.18.2. Product Portfolio
23.4.18.3. Key Financials
23.4.18.4. Sales Footprint
23.4.18.5. SWOT Analysis
23.4.18.6. Strategy Overview
23.4.18.6.1. Marketing Strategies
23.4.18.6.2. Channel Strategies
23.4.18.6.3. Product Strategies
23.4.19. Haohai Biological Technology
23.4.19.1. Overview
23.4.19.2. Product Portfolio
23.4.19.3. Key Financials
23.4.19.4. Sales Footprint
23.4.19.5. SWOT Analysis
23.4.19.6. Strategy Overview
23.4.19.6.1. Marketing Strategies
23.4.19.6.2. Channel Strategies
23.4.19.6.3. Product Strategies
23.4.20. Chroma Pharma
23.4.20.1. Overview
23.4.20.2. Product Portfolio
23.4.20.3. Key Financials
23.4.20.4. Sales Footprint
23.4.20.5. SWOT Analysis
23.4.20.6. Strategy Overview
23.4.20.6.1. Marketing Strategies
23.4.20.6.2. Channel Strategies
23.4.20.6.3. Product Strategies
24. Assumptions and Acronyms Used
25. Research Methodology
Explore Healthcare Insights
View Reports
Hyaluronic Viscosupplementation Market
